Recurrent Glioblastoma Market to Grow Positively at a Paltry CAGR | Companies- Ascletis Pharmaceuticals, VAXIMM AG, VBL Therapeutics, OX2 Therapeutics, Erasca, Genexine

(New York, Nevada, Las Vegas), DelveInsight's "Recurrent Glioblastoma - Market Insight, Epidemiology and Market Forecast - 2032" report provides current treatment practices, emerging drugs, Recurrent Glioblastoma market share of the individual therapies, current and forecasted Recurrent Glioblastoma market size from 2019 to 2032 segmented by seven major markets. The report also offers current Recurrent Glioblastoma therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Recurrent Glioblastoma market.

Request for a Free Recurrent Glioblastoma Market Sample Report @ https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Recurrent Glioblastoma Overview

Glioblastoma multiforme (GBM) is one of the most aggressive primary brain tumors, with a grim prognosis despite maximaltreatment. Advancements in the past decades have not significantly increased the overall survival of patients with this disease.The recurrence of GBM is inevitable, its management often unclear and case dependent. Tumor recurrence is the leading causeof death, and the rate of recurrence is rather high after initial treatment. Most patients (90%) experience recurrence in situ, andno significant relationship has been observed with the choice of therapy. Therefore, GBM recurrence has become a clinicallysignificant issue.

Recurrent Glioblastoma Causes

Recurrent Glioblastoma is caused by mutations in the F9 gene. The F9 gene is located on the X chromosome and thus is inheritedas an X-linked recessive trait. In about 30% of new cases of Recurrent Glioblastoma, the altered gene occurs spontaneouslywithout a previous family history.
Recurrent Glioblastoma Symptoms
GBM symptoms tend to come on quickly. The growing tumor puts pressure on the brain, causing: Blurred or double vision,Headaches, Loss of appetite, Memory problems, Mood or personality changes and Muscle weakness or balance problems.

Risk Factors

Glioblastoma risk factors are specific characteristics that can make a person more likely to develop this type of brain cancer.While the precise causes of Glioblastoma are largely unknown, researchers have identified a list of characteristics that manypatients have in common. While risk factors can be helpful for determining a person's likelihood of developing Glioblastoma, it'simportant to remember that: Many people who have one or more Glioblastoma risk factors never develop cancer; Some peopledevelop Glioblastoma without having any of the known risk factors.

Recurrent Glioblastoma Treatment

Treatment for a recurrent Glioblastoma often differs slightly from the treatments used to address an initial tumor. That'sbecause: Surgery may be an option, even if a patient already had surgery during the last round of treatment. However,oncologists will need to determine if the recurrent tumor can be safely resected and if the patient is healthy enough to undergo asecond operation. Radiation therapy is typically only given once. If a patient already had a course of traditional radiation therapy,an alternative (e.g., stereotactic radiosurgery) may be recommended instead. A different combination of chemotherapy drugswill likely be recommended for patients with recurrent Glioblastoma. If the same drugs are used the second time around, theymay be administered in stronger doses or accelerated delivery cycles.

Request for a Free Recurrent Glioblastoma Market Sample Report @ https://www.delveinsight.com/report-store/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Recent Breakthrough in the Recurrent Glioblastoma Market:

In January 2022, Ascletis Pharma announced the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent Glioblastoma (rGBM).
In May 2021, Ascletis Pharma announced that China National Medical Products Administration (NMPAapproved the clinical trial application of ASC40 combined with bevacizumab to treat patients with recurrent glioblastoma (rGBM) has been accepted for review by China NMPA.

Request for a Free Recurrent Glioblastoma Market Sample Report @ https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Recurrent Glioblastoma Treatment Market

The Recurrent Glioblastoma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Recurrent Glioblastoma market trends by analyzing the impact of current Recurrent Glioblastoma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Recurrent Glioblastoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Recurrent Glioblastoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Recurrent Glioblastoma market in 7MM is expected to witness a major change in the study period 2019-2032.

Request for a Free Recurrent Glioblastoma Market Sample Report @ https://www.delveinsight.com/report-store/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Promising Therapies in the Recurrent Glioblastoma Pipeline

ASC40 : Ascletis Pharmaceuticals
VXM01: VAXIMM AG
VB-111: VBL Therapeutics
hp1a8: OX2 Therapeutics
ERAS-801: Erasca
GX-I7: Genexine

Recurrent Glioblastoma Emerging Therapy Assessment

ASC40 : Ascletis Pharmaceuticals
ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de novolipogenesis (DNL). ASC40 inhibits energy supply and disturbs membrane phospholipid composition of tumorcells by blocking de novo lipogenesis. Approximately 80% of 180 patients with recurrent Glioblastoma (rGBM)in the Phase III clinical trial are expected to be randomized and enrolled by the end of December 2022.Currently the product is in Phase III stage of development for the treatment of recurrent Glioblastoma.


Discover more about Recurrent Glioblastoma therapies in the pipeline, visit Recurrent Glioblastoma Drugs @ https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Recurrent Glioblastoma Market

Ascletis Pharmaceuticals
VAXIMM AG
VBL Therapeutics
OX2 Therapeutics
Erasca
Genexine

To understand key companies related to the Recurrent Glioblastoma Market, get a snapshot of the Recurrent Glioblastoma Regulatory and Patent Analysis @ https://www.delveinsight.com/report-store/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Recurrent Glioblastoma Market Report

Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Recurrent Glioblastoma Companies: Ascletis Pharmaceuticals, VAXIMM AG, VBL Therapeutics, OX2 Therapeutics, Erasca, Genexine, and others
Key Recurrent Glioblastoma Pipeline Therapies: ASC40, VXM01, VB-111, hp1a8, ERAS-801, GX-I7, and others
Therapeutic Assessment: Recurrent Glioblastoma current marketed and emerging therapies
Recurrent Glioblastoma Market Dynamics: Recurrent Glioblastoma market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Recurrent Glioblastoma Market Access and Reimbursement

Table of Contents

1. Recurrent Glioblastoma Market Key Insights
2. Recurrent Glioblastoma Market Report Introduction
3. Recurrent Glioblastoma Market Overview at a Glance
4. Recurrent Glioblastoma Market Executive Summary
5. Disease Background and Overview
6. Recurrent Glioblastoma Treatment and Management
7. Recurrent Glioblastoma Epidemiology and Patient Population
8. Patient Journey
9. Recurrent Glioblastoma Emerging Drugs
10. 7MM Recurrent Glioblastoma Market Analysis
11. Recurrent Glioblastoma Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Recurrent Glioblastoma Market Drivers
15. Recurrent Glioblastoma Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:

Name: Kritika Rehani
E-mail: info@delveinsight.com
Phone: +1(919)321-6187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.